Zoledronic Acid - CAS 118072-93-8
Catalog number: 118072-93-8
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C5H10N2O7P2
Molecular Weight:
272.09
COA:
Inquire
Targets:
PKC
Description:
Zoledronic acid induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho.
Purity:
>98%
Synonyms:
Zoledronate, CGP-4244; CGP 4244; CGP4244
MSDS:
Inquire
InChIKey:
XRASPMIURGNCCH-UHFFFAOYSA-N
InChI:
InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)
Canonical SMILES:
C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O
1.Long-term leukopenia in a lung transplanted patient with cystic fibrosis treated with zoledronic acid: a case report.
Karahasanovic A1,2, Thorsteinsson AL3,4, Bjarnason NH5,6, Eiken P3,4. Osteoporos Int. 2016 Apr 14. [Epub ahead of print]
Cystic fibrosis (CF) is a serious autosomal recessive genetic disorder associated with chronic lung disease, malabsorption, malnutrition, pancreatic insufficiency and premature respiratory failure. Recent advances in medical science and technology have increased the lifespan of patients with CF, albeit with long-term consequences of the disease, such as osteoporosis, becoming of increasing significance. The medical treatment of osteoporosis in patients with CF or after organ transplantation is still being explored, and no clear guidelines regarding the best choice of bisphosphonate exist. We report a case of a young woman with CF, lung transplantation and low bone mass developing long-term leukopenia after treatment with zoledronic acid. The leukopenia, with a strong affection of the neutrocytes, lasted for 4 months and the condition only went into remission after granulocyte-colony stimulating factor (G-CSF) treatment. It is important to be aware of symptomatic leukopenia in immunosuppressive patients after treatment with zoledronic acid.
2.Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
Fanale D1, Amodeo V1, Bazan V1, Insalaco L1, Incorvaia L1, Barraco N1, Castiglia M1, Rizzo S1, Santini D2, Giordano A3, Castorina S4, Russo A1. Oncotarget. 2016 Apr 13. doi: 10.18632/oncotarget.8722. [Epub ahead of print]
Zoledronic acid (ZOL), belonging to third generation bisphosphonate family, is a potent inhibitor of osteoclast-mediated bone resorption, widely used to effectively prevent osteolysis in breast cancer patients who develop bone metastases. Low doses of ZOL have been shown to exhibit a direct anticancer role, by inhibiting cell adhesion, invasion, cytoskeleton remodelling and proliferation in MCF-7 breast cancer cells. In order to identify the molecular mechanisms and signaling pathways underlying the anticancer activity exerted by ZOL, we analyzed for the first time the microRNA expression profile in breast cancer cells. A large-scale microarray analysis of 377 miRNAs was performed on MCF7 cells treated with 10 μM ZOL for 24 h compared to untreated cells. Furthermore, the expression of specific ZOL-induced miRNAs was analyzed in MCF-7 and SkBr3 cells through Real-time PCR. Low-dose treatment with ZOL significantly altered expression of 54 miRNAs.
3.Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A1, Higuchi T1, Ozawa H1, Yanai A1, Miyagawa Y1, Murase K1, Imamura M1, Takatsuka Y1, Miyoshi Y2. Breast Cancer. 2016 Apr 4. [Epub ahead of print]
BACKGROUND: Bone-modifying agents are effective for treatment of breast cancer patients with bone metastases. Since their action is mediated through suppression of the osteoclast function, their efficacy can be determined by monitoring bone turnover markers. However, the clinical significance of these markers is yet to be compared.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PKC Products


CAS 151342-35-7 Ro 32-0432 hydrochloride

Ro 32-0432 hydrochloride
(CAS: 151342-35-7)

Ro 32-0432 hydrochloride is a selective and orally active inhibitor of PKC displaying a 10-fold greater selectivity for PKC-&alpha (IC50 = 9.3 nM); and a 4-fold...

NSC305787 hydrochloride
(CAS: 53868-26-1)

NSC305787 hydrochloride is a small molecule inhibitor of PKC (IC50=8.3 μM) that directly inhibits ezrin protein as an approach to prevent tumor metastasis.

CAS 169939-93-9 Ruboxistaurin Hydrochloride

Ruboxistaurin Hydrochloride
(CAS: 169939-93-9)

Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-m...

CAS 75567-37-2 Ingenol Mebutate

Ingenol Mebutate
(CAS: 75567-37-2)

Ingenol Mebutate is a substance found in the sap of the plant Euphorbia peplus and an inducer of cell death. It is effective for field treatment of actinic kera...

CAS 20449-79-0 Melittin

Melittin
(CAS: 20449-79-0)

Melittin is a polypeptide isolated from the venom of the honey bee (Apis mellifera). It inhibits protein kinase C, Ca2+/calmodulin-dependent protein kinase II, ...

Pseudo RACK1

Pseudo RACK1 is an activator of protein kinase C which is a family of protein kinase enzymes involved in controlling the function of other proteins through the ...

CAS 99026-78-5 [Ala113]-MBP (104-118)

[Ala113]-MBP (104-118)
(CAS: 99026-78-5)

[Ala113]-MBP (104-118) is a non-competitive inhibitor of PKC with IC50 value of 46-145 mM. It is a synthetic peptide analog of bovine myelin basic protein (MBP)...

CAS 425637-18-9 Sotrastaurin

Sotrastaurin
(CAS: 425637-18-9)

Sotrastaurin, also known as AEB-701, is an orally available pan-protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities....

Chemical Structure

CAS 118072-93-8 Zoledronic Acid

Quick Inquiry

Verification code

Featured Items